Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1

Randomized controlled trial published in Diabetes, obesity & metabolism (2026) covering Cagrilintide.

Randomized controlled trial.

The record

• Journal: Diabetes, obesity & metabolism 28(10): 9317-9325
• Published: 2026-07-26
• PMID: 42503495 — DOI: 10.1111/dom.71134
• MeSH terms: Humans, Obesity, Weight Loss, Blood Glucose, Triglycerides, Anti-Obesity Agents, Body Mass Index, Treatment Outcome, Double-Blind Method, Blood Pressure, Adult, Middle Aged, Female, Male, Glucagon-Like Peptides, Glycated Hemoglobin, Semaglutide
• Funding: Novo Nordisk A/S
• Author countries: Denmark, Ireland, Italy, UK, USA

Peptide profiles: Cagrilintide.

All indexed evidence: Cagrilintide trials & papers.

Related studies: Efficacy and safety of zalfermin co-administered with semaglutide in participants with…, Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2…, Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with…, Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with….